延长PFS近一年半，阿斯利康重磅BTK抑制剂获FDA优先审评资格
Oct 4, 2024 · 今日，阿斯利康（AstraZeneca）公司宣布，为布鲁顿氏酪氨酸激酶（BTK）抑制剂Calquence（acalabrutinib）递交的补充新药申请（sNDA）已经被美国FDA接受并 ...
AstraZeneca trumpets new Calquence combos in CLL - Fierce …
Jul 29, 2024 · AstraZeneca trumpets new Calquence combos in CLL. Can they change clinical practice? With a phase 3 trial win claimed by AstraZeneca, the heated BTK inhibitor race might see its first triplet...
Fixed-duration CALQUENCE plus venetoclax demonstrated …
5 days ago · CALQUENCE plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard of care in this setting. CALQUENCE plus venetoclax poised to become first...
Fixed-duration CALQUENCE plus venetoclax demonstrated
6 days ago · CALQUENCE plus venetoclax poised to become first all-oral fixed-duration regimen of a second-generation BTK inhibitor plus venetoclax in 1st-line CLL.
Fixed-duration Calquence plus venetoclax, - AstraZeneca
Jul 29, 2024 · Calquence As part of an extensive clinical development programme, Calquence is currently being evaluated as a single treatment and in combination with standard-of-care chemoimmunotherapy for patients with multiple B-cell blood cancers, including CLL, MCL and diffuse large B-cell lymphoma.
AstraZeneca reports ‘positive’ results from AMPLIFY Phase 3 trial
5 days ago · At a median follow up of 41 months, results showed Calquence plus venetoclax reduced the risk of disease progression or death by 35% compared to standard-of-care chemoimmunotherapy.
Calquence combination regimen demonstrated statistically …
May 2, 2024 · Incorporating Calquence into the first-line mantle cell lymphoma setting would give many more patients the opportunity to benefit from the robust efficacy and strong safety profile we’ve seen with this medicine.”
CALQUENCE® (acalabrutinib) granted Priority Review in the US …
Oct 3, 2024 · WILMINGTON, Del.-- (BUSINESS WIRE)--AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE ® (acalabrutinib) has been accepted and granted Priority Review in the US for the...
CALQUENCE combination regimen demonstrated statistically …
May 2, 2024 · CALQUENCE is a Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate.
CALQUENCE combination regimen demonstrated statistically …
May 2, 2024 · As part of an extensive clinical development program, AstraZeneca is currently evaluating CALQUENCE alone and in combination for the treatment of multiple B-cell blood cancers, including chronic...
Skip to content